Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

Budget 2018: UK life sciences sector delivers its verdict

UK Chancellor Philip Hammond delivered a budget that was broadly pro-business but contained mixed news for the life sciences industry, according to two industry bodies.The headline news of an additional...

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

- PMLiVE

Hancock’s ‘Tech Revolution’ for NHS to be limited by budgets

Vision for a tech-driven NHS unveiled, but is there money to fund it?

Roche Basel Switzerland

Roche preps new Kadcyla filings after phase 3 trial win

Says the drug significantly reduced IDFS in women with residual disease

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

- PMLiVE

Roche gets wider approval for haemophilia drug Hemlibra

Approved to treat bleeding episodes in patients without inhibitors

- PMLiVE

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

Roche Basel Switzerland

Roche drug hits the mark in spinal muscular atrophy studies

Data suggests Risdiplam could improve motor function

Eli Lilly HQ

Lilly gets EMA nod for Verzenio in breast cancer

And puts pressure on Pfizer’s market leading Ibrance and Novartis’ Kisqali

- PMLiVE

Hancock says UK genome service is now ‘rolling out’

Health secretary also announces a £240m social care boost

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links